Odanacatib, also known as MK-0822, is an inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K, which may result in a reduction in bone resorption, improvement of bone mineral density, and a reversal in osteoporotic changes. Cathepsin K, a tissue-specific cysteine protease that catalyzes degradation of bone matrix proteins such as collagen I/II, elastin, and osteonectin plays an important role in osteoclast function and bone resorption. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
Cysteine Protease Inhibitors Related Prodcuts:
E-64; PMSF; Balicatib; Pepstatin A; Leupeptin hemisulfate; Aloxistatin